MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
November 30, 2020 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
September 21, 2020 07:30 ET | MacroGenics, Inc.
$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage...